Evaluation of patient adherence to artemether-lumefantrine (AL) obtained from public and private drug outlets in Tanzania

Not Applicable

Completed

• Conditions: Malaria; Infections and Infestations; Unspecified malaria

• Registration Number: ISRCTN83765567
• Lead Sponsor: ondon School of Hygiene and Tropical Medicine (UK)

Brief Summary

2014 results in https://www.ncbi.nlm.nih.gov/pubmed/25002300 (added 29/11/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2012-12-31
• Study Start: 2013-01-16
• Last Update Posted: 6 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1014

Inclusion Criteria

Male and female patients of all ages attending health facilities and drug stores during the week of the study will be eligible for inclusion (i.e. follow-up visit) if they are seeking treatment for fever or malaria for themselves or on behalf of someone else, and they are dispensed AL (health facilities) or purchase AL (drug shops).

Exclusion Criteria

Patients will be excluded from follow-up if they reside further than 10 km away from the drug outlet or if another family member was previously followed-up and interviewed by the study team.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Patient adherence to AL is the primary outcome indicator and will be reported in two ways:<br> 1. Patient took all expected doses of AL in three to four days<br> 2. Patient took all expected doses of AL at six time points at different times of day between three and four times of day<br>

Secondary Outcome Measures

Name	Time	Method
Score of dispenser knowledge of advice to provide when dispensing AL (from dispenser interviews)